Clinical trials · New York
Cardiomyopathies clinical trials in New York
We’re tracking 32 recruiting cardiomyopathies studies with a site in New York — including Phase 1, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06610019Recruiting
Heart imaging study using MRI
This study uses heart MRI scans to learn more about cardiovascular health in adults. If you are 18 or older and have been referred for a heart MRI at Montefiore, you may be able to join.
The Bronx, New YorkAges 18 years+ - NCT07814079Recruiting
Targeted ablation for ventricular tachycardia
This study tests a targeted approach to treat ventricular tachycardia (a fast, abnormal heart rhythm) by finding and destroying the specific scar tissue in the heart that causes it. The goal is to improve the success of the standard ablation procedure.
Valhalla, New YorkAges 18 years+ - NCT07771465RecruitingPhase 3
Long-term safety of danicamtiv for genetic dilated cardiomyopathy
This study checks the long-term safety and effectiveness of the drug danicamtiv in people with a genetic form of dilated cardiomyopathy, a condition where the heart muscle becomes weak and enlarged. If you've already completed the earlier DAN-301 study, this trial continues to monitor you while you keep taking the medication.
New York, New YorkAges 18 years+ - NCT07755904RecruitingPhase 3
New study drug compared with metoprolol for hypertrophic cardiomyopathy
This trial compares a new study drug (BHB-1893) with a standard heart medication called metoprolol to see which one better improves symptoms in people with obstructive hypertrophic cardiomyopathy. If you join, you will be randomly assigned to receive either the study drug or metoprolol, and your symptoms and heart function will be monitored over time.
Manhasset, New YorkAges 18–85 - NCT06311708Recruiting
PKP2-related heart condition natural history study
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
New York, New YorkAges 14–65 - NCT07210723RecruitingPhase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
New York, New YorkAges 18 years+ - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
New York, New YorkAges 18–85 - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
New York, New YorkAges 18 years+ - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
New York, New YorkAges 18 years+ - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
New York, New YorkAges 18–75 - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
New York, New YorkAges 18–90 - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
New York, New YorkAges 18 years+ - NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Cooperstown, New YorkAges 18 years+ - NCT05302271RecruitingPhase 1
Gene therapy for the heart problems in Friedreich's ataxia
This trial tests a one-time gene therapy that delivers a corrected copy of the frataxin gene directly to the heart. It aims to improve or stabilize heart function in people with Friedreich's ataxia who have early or advanced heart involvement.
New York, New YorkAges 12–50 - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
The Bronx, New YorkAges 18 years+ - NCT03663348Recruiting
Patient registry for Takotsubo (stress) heart syndrome
This study is a patient registry that collects information from people diagnosed with Takotsubo syndrome, also known as a stress-related heart condition. It may help researchers learn more about who is affected and how the condition behaves over time.
New York, New YorkAges 18–110 - NCT07814118Enrolling by invitation
Understanding how your body works during routine care
This study looks at how different body systems work together in people with various conditions and healthy volunteers. It uses routine medical tests and data to understand health better, which can help improve future care.
New York, New YorkAges 18 years+ - NCT06228924RecruitingPhase 1
Gene therapy for ARVC with PKP2 mutation
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
New York, New YorkAges 18–65 - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
New York, New YorkAges 18 years+ - NCT06976606Recruiting
A study of adults with PKP2-linked arrhythmogenic cardiomyopathy
This study follows people with a confirmed PKP2 genetic mutation and arrhythmogenic cardiomyopathy (ACM) to understand how their condition changes over time. It may help doctors learn more about the disease and plan future treatments.
Rochester, New YorkAges 18–65 - NCT06964464RecruitingPhase 4
Comparing two heart failure medications in ICD patients
This trial compares two beta-blocker medications, carvedilol and metoprolol succinate, to see which one works better for people with heart failure who have an implantable cardioverter defibrillator (ICD). If you are currently taking metoprolol succinate, you may be able to switch to carvedilol and help researchers find the best treatment.
Brooklyn, New YorkAges 18 years+ - NCT06800716Recruiting
Impella temporary pump for end-stage heart failure
This study tests whether using a temporary heart pump called Impella 5.5 can help strengthen a very weak and enlarged heart (dilated cardiomyopathy) in people who are waiting for a heart transplant. If you qualify, the pump is placed to support your heart temporarily, and the research team will check how your heart responds.
New York, New YorkAges 18 years+ - NCT06699056Recruiting
AI heart monitor study for ejection fraction
This study uses an AI-powered wearable monitor to check how well your heart pumps blood (ejection fraction) from a simple EKG recording. It may help doctors quickly assess heart function without extra tests.
New York, New YorkAges 18 years+ - NCT05650658Recruiting
Compare two heart pacing options in people with weak heart function
This trial compares two types of “left-side” heart pacing to see which one works better in people with weak heart pumping. It may help guide the best pacing choice for improving heart function and symptoms.
New York, New YorkAges 18 years+
Cardiomyopathies trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cardiomyopathies studies listed above.
- Columbia University Irving Medical Center · 6 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 5 studies
- NYU Langone Health · 5 studies
- Clinical Trial Site · 2 studies
- Columbia University Irving Medical Center / NewYork-Presbyterian · 2 studies
- New York University (NYU) School of Medicine - Langone Medical Center · 2 studies
- University of Rochester · 2 studies
- Weill Cornell Medicine · 2 studies
What taking part in a cardiomyopathies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cardiomyopathies trials in other states
Common questions
- Are there cardiomyopathies clinical trials in New York?
- Yes. We're currently tracking 32 recruiting cardiomyopathies studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cardiomyopathies study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cardiomyopathies studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.